Arthritis & Rheumatism, Volume 60,
October 2009 Abstract Supplement
The 2009 ACR/ARHP Annual Scientific Meeting
Philadelphia October 16-21, 2009.
ADAMTS5 Is a Biomarker for Prediction of the Response to Infliximab in Patients with Rheumatoid Arthritis
Tsuzaka1, Kensei, Itami1, Yuka, Amano2, Koichi, Takeuchi3, Tsutomu
To identify a biomarker for prediction of the response to infliximab (INF) in rheumatoid arthritis patients, we focused on a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) that seems to play a key role in aggrecan degradation in cartilage.
Fourty-four randomly selected active RA patients were treated with INF. Peripheral blood samples were collected at baseline and ADAMTS5 mRNA was quantified using real-time PCR.
Baseline ADAMTS5 mRNA levels in the responder (1.461 ± 0.817) was significantly (p=0.0090) lower than that in the non-responder (2.246 ± 1.350) at 62 weeks' treatment with INF. The DAS28 at 62 weeks' treatment was significantly (p=0.0003) lower in the Low-ADAMTS5 group (2.47 ± 1.50) than in the High-ADAMTS5 group (4.46 ± 1.76). The percent reduction of the DAS28 (%DAS28 reduction) was significantly (p=0.0015) higher in the Low-ADAMTS5 group (52.8 ± 7.25) than in the High-ADAMTS5 group (22.5 ± 5.21). Interestingly, significant correlations were observed between the DAS28 and %DAS28 reduction at 62 weeks (p<0.001; r= 0.56 and -0.60, respectively) and the baseline ADAMTS5 mRNA level. Furthermore, DHAQ, an estimate of the improvement in the HAQ score, at 62 weeks' treatment was significantly (p=0.0305) higher in the Low-ADAMTS5 group (0.70 ± 0.68) than in the High-ADAMTS5 group (0.25 ± 0.35). The positive predictive value of a low baseline ADAMTS5 level for predicting good response and remission (DAS28<2.6 at 62 weeks) was 80.0% and 73.3%, respectively.
The baseline ADAMTS5 mRNA level is a candidate biomarker for prediction of the response to INF in RA patients.
To cite this abstract, please use the following information:
Tsuzaka, Kensei, Itami, Yuka, Amano, Koichi, Takeuchi, Tsutomu; ADAMTS5 Is a Biomarker for Prediction of the Response to Infliximab in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheum 2009;60 Suppl 10 :918